HC Wainwright Reiterates “Buy” Rating for Invivyd (NASDAQ:IVVD)

Invivyd (NASDAQ:IVVD)‘s stock had its “buy” rating reiterated by research analysts at HC Wainwright in a research report issued to clients and investors on Tuesday, Benzinga reports. They currently have a $15.00 price objective on the stock.

Invivyd Stock Performance

Shares of IVVD opened at $0.91 on Tuesday. The company’s 50 day moving average price is $0.99 and its 200 day moving average price is $1.41. Invivyd has a 52 week low of $0.81 and a 52 week high of $5.20. The company has a market capitalization of $108.59 million, a PE ratio of -0.49 and a beta of 0.63.

Invivyd (NASDAQ:IVVD) last announced its quarterly earnings data on Wednesday, August 14th. The company reported ($0.40) EPS for the quarter, missing analysts’ consensus estimates of ($0.37) by ($0.03). The company had revenue of $2.26 million for the quarter, compared to analysts’ expectations of $4.91 million. On average, equities analysts forecast that Invivyd will post -0.6 earnings per share for the current fiscal year.

Institutional Trading of Invivyd

Institutional investors have recently added to or reduced their stakes in the business. Chase Investment Counsel Corp acquired a new stake in shares of Invivyd in the first quarter worth $271,000. SG Americas Securities LLC acquired a new stake in shares of Invivyd in the first quarter worth $56,000. Vanguard Group Inc. lifted its stake in shares of Invivyd by 3.9% in the first quarter. Vanguard Group Inc. now owns 2,611,202 shares of the company’s stock worth $11,594,000 after buying an additional 97,496 shares during the last quarter. Acadian Asset Management LLC acquired a new stake in shares of Invivyd in the first quarter worth $905,000. Finally, Jacobs Levy Equity Management Inc. raised its stake in Invivyd by 21.7% during the 1st quarter. Jacobs Levy Equity Management Inc. now owns 435,338 shares of the company’s stock valued at $1,933,000 after purchasing an additional 77,603 shares during the last quarter. 70.36% of the stock is currently owned by institutional investors and hedge funds.

Invivyd Company Profile

Invivyd, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. The company developed INVYMAB, a platform that combines viral surveillance and predictive modeling with advanced antibody engineering.